Literature DB >> 18066075

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.

Andrew M Tager1, Peter LaCamera, Barry S Shea, Gabriele S Campanella, Moisés Selman, Zhenwen Zhao, Vasiliy Polosukhin, John Wain, Banu A Karimi-Shah, Nancy D Kim, William K Hart, Annie Pardo, Timothy S Blackwell, Yan Xu, Jerold Chun, Andrew D Luster.   

Abstract

Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066075     DOI: 10.1038/nm1685

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  286 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Shape shifting.

Authors:  Bob Baltera
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

Review 3.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 4.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

5.  Seeing the future of bioactive lipid drug targets.

Authors:  Jilly F Evans; John H Hutchinson
Journal:  Nat Chem Biol       Date:  2010-07       Impact factor: 15.040

Review 6.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 7.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 8.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

9.  The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis.

Authors:  Long Shuang Huang; Biji Mathew; Haiquan Li; Yutong Zhao; Shwu-Fan Ma; Imre Noth; Sekhar P Reddy; Anantha Harijith; Peter V Usatyuk; Evgeny V Berdyshev; Naftali Kaminski; Tong Zhou; Wei Zhang; Yanmin Zhang; Jalees Rehman; Sainath R Kotha; Travis O Gurney; Narasimham L Parinandi; Yves A Lussier; Joe G N Garcia; Viswanathan Natarajan
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

10.  LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.

Authors:  Norihiko Sakai; Jerold Chun; Jeremy S Duffield; Takashi Wada; Andrew D Luster; Andrew M Tager
Journal:  FASEB J       Date:  2013-01-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.